Pharming (PHAR) Return on Capital Employed (2021 - 2026)
Pharming (PHAR) posted Return on Capital Employed of 2.85% for Q1 2026, down 33.11% on a QoQ basis from 4.26% in Q4 2025, and up 1024.0% year-over-year from 0.25% in Q1 2025.
Pharming (PHAR) Return on Capital Employed (2021 - 2026) Analysis & Trends
Pharming's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 2.85% for Q1 2026.
- Quarterly Return on Capital Employed rose 1024.0% year-over-year to 2.85% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.85% (up 1024.0% YoY) and the FY2025 annual result came in at 7.73%, up 1014.0% from the prior year.
- Return on Capital Employed was 2.85% for Q1 2026 at Pharming, down from 4.26% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 2163478.02% in Q1 2024 and bottomed at 7.39% in Q1 2025.
- A 5-year average of 382791.57% and a median of 1.25% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 216346698 bps — and 2025, when it plunged 216348541 bps.
- Pharming's Return on Capital Employed stood at 0.03% in 2022, then soared by 2000000000 bps to 1425906.7% in 2023, then slumped by 100 bps to 7.07% in 2024, then jumped by 160 bps to 4.26% in 2025, then plunged by 33 bps to 2.85% in 2026.
- Business Quant data shows PHAR's Return on Capital Employed at 2.85% in Q1 2026, 4.26% in Q4 2025, and 1.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Pharming | 8.69 Bn | 8.64 Bn | 65.80 Mn | 2.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.85% |
| Dec 31, 2025 | 4.26% |
| Sep 30, 2025 | 1.93% |
| Jun 30, 2025 | -1.34% |
| Mar 31, 2025 | -7.39% |
| Dec 31, 2024 | -7.07% |
| Sep 30, 2024 | -4.50% |
| Jun 30, 2024 | -5.02% |
| Mar 31, 2024 | 2,163,478.02% |
| Dec 31, 2023 | 1,425,906.70% |
| Sep 30, 2023 | 1,451,749.12% |
| Jun 30, 2023 | 1,466,328.55% |
| Mar 31, 2023 | 11.04% |
| Dec 31, 2022 | 0.03% |
| Sep 30, 2022 | 0.01% |
| Jun 30, 2022 | 1.25% |
| Mar 31, 2022 | -1.75% |
| Dec 31, 2021 | 0.42% |
| Sep 30, 2021 | 14.23% |
| Jun 30, 2021 | 0.04% |